Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial
NeurologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publicado em
- 20 jun 2025
- Citações
- 23
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial
Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou, Hervé Perrier, Faiza Khemissa Akouz, Romain Desgrippes, Marie-Pierre Galais, Chloé Janiszewski, Thibault Mazard, Yves Rinaldi et al.
Descritores MeSH
- Colonic Neoplasms
- Organoplatinum Compounds
- Peripheral Nervous System Diseases
- Antineoplastic Combined Chemotherapy Protocols
- Neurotoxicity Syndromes
- Fluorouracil
- Oxaliplatin
- Male
- Middle Aged
- Neoplasm Staging
Veja também
Estudos relacionados
- Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial
- Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial
- Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
- Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis